Now, Gilead has conducted an analysis of a phenomenon that can undermine all infectious disease therapies, including ...

Dr Robert Mutumba, the head of the Aids Control Programme at the Ministry of Health, told Daily Monitor that Ugandans are ...

Merck (MRK) announced on Wednesday that its single-tablet antiviral regimen, doravirine and islatravir for adults with HIV, was found to be non-inferior to Gilead’s (GILD) once-daily HIV pill Biktarvy ...

Please provide your email address to receive an email when new articles are posted on . For the first time, adolescents with HIV have the option of a two-drug, single-tablet oral treatment regimen.

The Food and Drug Administration has approved a highly effective new HIV-prevention medication, Gilead Sciences reported Wednesday. In clinical trials, the drug nearly eliminated HIV’s spread among ...

(Reuters) -Gilead Sciences said on Thursday a late-stage study showed its long-acting injectable drug was more effective in preventing HIV infection in women compared to its existing daily pill ...

(Reuters) -The U.S. Food and Drug Administration has paused Gilead Sciences' trials testing a combination of two of its experimental HIV treatments due to low levels of a type of white blood cell in ...

The quest for a single-pill once-a-day treatment for HIV became a reality when the FDA approved Atripla on July 12. It combines the already approved drugs efavirenz (Sustiva), tenofovir (Viread), and ...

In patients with HIV infection on rifampicin TB therapy, twice-daily bictegravir/emtricitabine/tenofovir alafenamide results ...

HUNTSVILLE, AL (WAFF) - Sept. 18 marks National HIV/AIDS and Aging Awareness Day. Older Americans are more likely than younger Americans to be diagnosed with HIV infection late in the course of their ...

You can now live a long and healthy life with HIV, thanks largely to medication that has turned it from a fatal infection and terminal illness into a chronic but manageable condition. Antiretroviral ...